EASY PIZZA TOAST


I’m so often ásked for eásy recipe ideás for kids. Both recipes they’ll love ánd recipes they cán máke themselves. Ánd luckily for me I háve two very eáger pre-teens reády to pláy guineá pig whenever I come up with á new ideá.
Eásy pizzá toást is the ultimáte áfter school snáck for kids (ánd the ádults will love it too). Use ány toppings of your choice in this 5-minute treát.
Course: Eásy, Kid friendly, Lunch, Pizzá, Snáck, Toást
Cuisine: Ámericán
Keyword: Áfter school snáck, eásy lunch recipe, Pizzá toást
Servings: 4
Cálories: 175 kcál
Áuthor: Álidá Ryder
Ingredients
·         4-8 slices breád of your choice toásted
·         1 cup Pizzá sáuce
·         1-2 cups gráted mozzárellá
·         ............
·         .............
Instructions
Full Instruction : ALL YOU CAN EAT
A renewed debate over health care and pharmaceutical prices flared up in 2016. The Obama White House, dismayed about rising prescription drug costs since the passing of the Affordable Care Act (ACA), wants new powers to regulate the industry. Republicans, industry operatives and free market advocates stand in opposition to the president's plans, claiming the proposed changes will do more harm than good. The debate may determine the future of health care policy in the United States. Nevertheless, pharmaceutical investors should be alert to potential downward price pressure, no matter the outcome on Capitol Hill. Argument in Favor of Government Intervention The Obama administration signed an executive order in January to limit the amount pharmaceutical companies can charge for drugs. By May, Congress began hearings on an overhaul of Medicare Part B to allow greater government control over pricing mechanisms. This would amount to a price ceiling on pharmaceutical products. The turning point in the drug debate may have been the sudden spike in prices for Daraprim, a treatment for parasite infections, and cycloserine, which is designed to battle tuberculosis. The cost of Daraprim rose from $13.50 to $750 per tablet after being acquired by Turing Pharmaceuticals. Cycloserine jumped from $16.67 per tablet to $360 per tablet once Rodelis Therapeutics purchased its rights. Several other drugs, notably the antibiotic doxycycline, have experienced similar price increases since 2013. Major news outlets, particularly the New York Times, expressed outrage at pharmaceutical companies and hedge fund financiers for exploiting sick people. Public outcry followed, and Congress spearheaded several investigations into corporate practices. There are legitimate concerns about whether pharmaceutical companies operate as de facto monopolies and are able to restrict supply to drive up prices. Argument in Favor of Free-Market Principles It is very difficult to prove the net effect of regulations. Economists cannot run trials before policy experiments. The best economics can do is highlight the most likely outcomes and then look for supporting evidence. Fortunately, when viewed through this prism, the obvious conclusion – regulations and restrictions limit competition and harm consumers – receives support from the historical results. Using this logic, the government should do less to help lower drug costs, not more. Dean Baker, economist and the co-director of the Center for Economic and Policy Research, says the pharma industry "has all of the problems economics predicts when government interferes with the market." The U.S. health care cost crisis did not exist before 1965. Until 1964, health care costs rose at nearly identical rates to the Consumer Price Index (CPI), according to U.S. Census Bureau data. Pharmaceutical research costs and drug prices rose an average of 3% between 1935 and 1965, barely above the 2.8% CPI for the same period. Medicare and Medicaid were enacted in 1965, further removing consumers from the cost of their medications. Thereafter, doctors and hospitals were increasingly reimbursed through cost formulas and received fees for service instead of receiving income based on quality and results. This crippled the vital role of consumer discrimination against high costs or ineffective treatment. Extreme limits on pharmaceutical competition make matters worse. in 1962 the Food and Drug Administration (FDA) enacted the Kefauver-Harris Amendment, making it much more difficult to receive approval for a new drug. In 1972, the Nixon administration passed laws forbidding the construction of new hospitals without a federal certificate of need. Research from RAND showed the cost of a day in the hospital increased approximately 1,000% between 1972 and 2012. Prices Would Go Down If Competition Were Legal It is practically impossible for new entrants to compete in the pharmaceutical industry. In 2003, the Tufts Center for the Study of Drug Development published a study in the Journal of Health Economics titled "The price of innovation: new estimates of drug development costs." It estimated the average cost of bringing a single new drug to market was $1 billion in 2000. Tufts performed another study in 2014 and found costs were up more than 250%; the cost of introducing a new drug was nearly $2.6 billion. If you include post-approval development expenses, such as indications and dosage strength studies, the actual life-cycle cost was $2.9 billion. The study found an "intense effort by companies to increase efficiency in R&D," but those were more than offset due to the increased complexity of trials and regulatory controls. The $3 billion it takes to introduce a drug is only the beginning. New companies need a good relationship with the FDA and the U.S. patent office to have any chance at approval. Drug patents are extremely generous, especially after the Reagan administration granted 20-year extensions in the 1980s. The limits on competition strangle innovation. Baker says this government-protected monopoly "allows drug companies to sell their drugs at prices that can be hundreds of time the free market price." insurance quote ireland,insurance quotes florida,insurance quotes texas,insurance rates by car,insurance quotes online,insurance quote comparison,insurance rates,insurance comparison,insurance,insurance quotes cheap,insurance endorsement,insurance for new drivers,insurance companies,insurance leads,insurance yuma az,insurance estimator,insurance groups,insurance premium,insurance companies near me,insurance times,insurance 24,insurance land,insurance check,insurance for a month,insurance 360,insurance yakima,insurance lapse,insurance king,insurance history,insurance value chain,insurance 321,insurance price check,insurance sales,insurance lawyer,insurance quote ontario,insurance logo,insurance agent,insurance services office,insurance line,insurance 6 months,insurance zip code,insurance management,insurance 2 wheeler,insurance adjuster,insurance in french,insurance calculator,insurance database,insurance one,insurance broker,insurance hire car,insurance usa,insurance post,insurance card,insurance risk,insurance deductible,insurance group 1 cars,insurance meaning,insurance types,insurance declaration page,insurance excess,insurance quote geico,insurance geico,insurance health card,insurance in germany,insurance on the spot,insurance zone,insurance news,insurance nation,insurance act,insurance underwriting process,insurance industry,insurance 2 go,insurance training,insurance services,insurance solutions,insurance marketplace,insurance insider,insurance nz,insurance number,insurance noodle,insurance network,insurance specialist,insurance 50/50,insurance market,insurance nexus,insurance reimbursement,insurance 365,insurance journal,insurance 80/20,insurance zenith,insurance two wheeler,insurance 7702,insurance works,insurance 2018,insurance rider,insurance hound,insurance zipcar,insurance license,insurance sales jobs,insurance supermarket,insurance emporium,insurance auto auction,insurance jobs london,insurance university,insurance 220 license,insurance verification,insurancewith,insurance product information document,insurance jobs manchester,insurance 21,insurance europe,insurance exam,insurance jobs near me,insurance jobs,insurance test,insurance winnipeg,insurance 99223,insurance 1st central,insurance 4 car hire review,insurance adjuster jobs,insurance underwriter salary,insurance 101,insurance in blackjack,insurance 4 car hire,assurance wireless,insurance 80/20 rule,insurance companies in japan,insurance ombudsman,insurance jobs in dubai,insurance 02,insurance 0800,insurance 10e,insurance 11e,insurance 125cc,insurance 3rd party bike,insurance 4 my caravan,insurance 4 sport,insurance 5,insurance 5 years,insurance 5000,insurance 6 points,insurance 7,insurance 77015,insurance 79936,insurance 7e,insurance 8e,insurance 8th street,insurance 9,insurance 90 day waiting period,insurance 94,insurance 9e,insurance act 2015,insurance age,insurance as a service,insurance development forum,insurance factory,insurance for foreigners in japan,insurance green card,insurance hero,insurance history check,insurance hunter,insurance in france,insurance in japanese,insurance initiatives ltd,insurance institute of ireland,insurance ireland,insurance jobs ipswich,insurance jobs leeds,insurance kerala,insurance kereta,insurance malaysia,insurance meaning in urdu,insurance news net,insurance premium tax vat,insurance protector,insurance underwriters uk,insurance united against dementia,insurance validity,insurance x,insurance xchange,insurance xpress,insurance yaletown Health care and pharmaceutical costs keep rising thanks to these structural challenges and protected profits. As Game Show Network president and medical author David Goldhill explains, "Accidentally, but relentlessly, America has built a health care system with incentives that inexorably generate terrible and perverse results." Prices Might Go Down Anyway in the Short Run The NASDAQ Biotechnology Index fell from above 3,600 to below 2,900 between October 2015 and May 2016. This is more than a 20% decline. Angry consumers and fear of extra innovation may be key drivers of price pressure on pharmaceutical stocks. In response, health insurers have pushed for so-called "value-based" deals to get price discounts from drug manufacturers. PricewaterhouseCoopers reported that drug prices "reached a boiling point" in the U.S. thanks to pressure from insurers and patients, and that insurance companies can use unfavorable sentiment and declining pharmaceutical equity performance to negotiate lower costs.